MRK
$79.86
Merck &
($.20)
(.25%)
MRK
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  $1.35
Revenue:  $12.65 Bil
Tuesday
Jan 26
6:45 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Tuesday, October 27, 2020

What do you expect when MRK reports earnings?
Beat
Meet
Miss

Where is MRK's stock price going from here?
Up
Flat
Down
Stock chart of MRK
Analysts
Summary of analysts' recommendations for MRK
Score
Grade
Pivots
Resistance
$81.63
$81.15
$80.51

$80.03

Support
$79.39
$78.91
$78.27
Tweet
Growth
Description
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbZoetisPfizerJohnson & JohnsonEli LillyUltragenyx Pharmaceutical